EIDD-2801

EIDD-2801 is an orally bioavailable prodrug of the potent ribonucleoside analog EIDD-1931. EIDD-2801 displays broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 could be potentially useful for COVID-19 treatment.